Skip to content

Study · Not a test of the peptide alone · 1994

4 results

[Endolymphatic chemotherapy and immunocorrection in patients with kidney and bladder cancers].

Serniak PS, Geev IuV, Prilutskiĭ AS

Urologiia i nefrologiia1 Sept 1994

PMID7871624 (opens in a new tab)PepBankPUB-07871624
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

  1. 01HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In kidney or bladder cancer patients, treatment with endolymphatic thymalin and polychemotherapy improved quality of life.

    In plain wordsIn kidney or bladder cancer patients, treatment with thymalin and chemotherapy improved quality of life.

    Peptide
    Thymalin
    Outcome
    IncreaseQuality of life
    Study

    n = 44

    Outcome group
    Quality of life · Whole body

    Source sentences

    Summary
    Endolymphatic introduction of immunocorrective thymalin improved the patients' life quality, their immune status.
    1 context sentence
    Summary · context
    However, the level and proportional expression of differential lymphocyte antigens following course polychemotherapy and immunocorrection in patients do not coincide with relevant parameters of healthy subjects.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  2. 02HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In kidney or bladder cancer patients, treatment with endolymphatic thymalin and polychemotherapy improved immune status.

    In plain wordsIn kidney or bladder cancer patients, treatment with thymalin and chemotherapy improved immune status.

    Peptide
    Thymalin
    Outcome
    IncreaseImmune status
    Study

    n = 44

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Endolymphatic introduction of immunocorrective thymalin improved the patients' life quality, their immune status.
    1 context sentence
    Summary · context
    However, the level and proportional expression of differential lymphocyte antigens following course polychemotherapy and immunocorrection in patients do not coincide with relevant parameters of healthy subjects.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  3. 03HumanNot a test of Thymalin aloneNon-randomized trialOther

    In kidney or bladder cancer patients, lymphocyte antigen levels after polychemotherapy and thymalin immunocorrection differed from healthy subjects.

    In plain wordsIn cancer patients, lymphocyte antigen levels after chemotherapy and thymalin differed from healthy subjects.

    Peptide
    Thymalin
    Outcome
    Not applicableDifferential lymphocyte antigen level
    Study

    n = 44

    Comparator
    Healthy subjects
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    However, the level and proportional expression of differential lymphocyte antigens following course polychemotherapy and immunocorrection in patients do not coincide with relevant parameters of healthy subjects.
    1 context sentence
    Summary · context
    Immunological examination and endolymphatic treatment were performed in 44 patients with cancer of the kidney or urinary bladder.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  4. 04HumanNot a test of Thymalin aloneNon-randomized trialOther

    In kidney or bladder cancer patients, proportional lymphocyte antigen expression after polychemotherapy and thymalin immunocorrection differed from healthy subjects.

    In plain wordsIn cancer patients, proportional lymphocyte antigen expression after chemotherapy and thymalin differed from healthy subjects.

    Peptide
    Thymalin
    Outcome
    Not applicableDifferential lymphocyte antigen proportional expression
    Study

    n = 44

    Comparator
    Healthy subjects
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    However, the level and proportional expression of differential lymphocyte antigens following course polychemotherapy and immunocorrection in patients do not coincide with relevant parameters of healthy subjects.
    1 context sentence
    Summary · context
    Immunological examination and endolymphatic treatment were performed in 44 patients with cancer of the kidney or urinary bladder.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.